A few other tidbits from today we didn’t mention amid the merger mayhem…

-Surface Logix has raised $20M for their obesity drug – congrats. [Xconomy]

-Insider trading at Schering-Plough? Check out this piece… [WSJ Deal Journal]

-Schering-Plough’s CEO Fred Hassan will get a nice exit package – $59M. [BNET Pharma]

-Human Genome Sciences’ Albuferon for hepatitis C good, but not good enough, shares nosedive. [Yahoo!Finance]

-It’s almost showtime for Avastin’s glioma data. [Yahoo!Finance]

-Obama’s new stem policy sends stem cell stocks in the green. [The Associated Press]

-Arana’s psoriasis drug meets endpoint…will Cephalon up its bid? [The Age]

-Mannkind buying Pfizer’s insulin facility…why? [BioSpace]

-Victory Pharma gets infused with $45M from Essex Woodlands for continued Naprelan sales. [PR Newswire]

-The New York Times tells the common folk what us biotechs already know: THERE’S NO WAY OUT!!! [The New York Times]

Image from smugmug

Related Posts